#pedksy

J&J submits sBLA for ustekinumab to treat children with ulcerative colitis 2 years and up | Contemporary Pediatrics If approved, this UC indication would add to pediatric indications of ustekinumab for psoriasis and active psoriatic arthritis.

ICYMI:

J&J has submitted a supplemental Biologics License Application to the FDA for ustekinumab (Stelara), seeking an expanded indication to include children 2 years and older with moderately-to-severely active ulcerative colitis. #pedksy

DETAILS: www.contemporarypediatrics.com/view/j-j-sub...